Analysis of ArriVent BioPharma Inc (AVBP)’s performance, earnings and valuation

Nora Barnes

ArriVent BioPharma Inc [AVBP] stock prices are up 10.14% to $25.2 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVBP shares have gain 12.15% over the last week, with a monthly amount glided 14.49%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

ArriVent BioPharma Inc [NASDAQ: AVBP] stock has seen the most recent analyst activity on December 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $45. Previously, Truist started tracking the stock with Buy rating on November 25, 2025, and set its price target to $43. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $37 on March 20, 2025. Guggenheim initiated its recommendation with a Buy and recommended $45 as its price target on March 10, 2025. Oppenheimer started tracking with an Outperform rating for this stock on July 22, 2024, and assigned it a price target of $35. In a note dated April 30, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $25 on this stock.

The stock price of ArriVent BioPharma Inc [AVBP] has been fluctuating between $15.47 and $29.71 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. ArriVent BioPharma Inc [NASDAQ: AVBP] shares were valued at $25.2 at the most recent close of the market. An investor can expect a potential return of 74.6% based on the average AVBP price forecast.

Analyzing the AVBP fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.6 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

It’s worth pointing out that ArriVent BioPharma Inc [NASDAQ:AVBP]’s Current Ratio is 14.90. Also, the Quick Ratio is 14.90, while the Cash Ratio stands at 5.23.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.